Citalopram versus other antidepressants for depression
by ncbi.nlm.nih.gov
Major depression is a severe mental illness characterised by a persistent and unreactive low mood and loss of all interest and pleasure, usually accompanied by a range of symptoms including appetite change, sleep disturbance, fatigue, loss of energy, poor concentration, psychomotor symptoms, inappropriate guilt and morbid thoughts of death. Antidepressant drugs remain the mainstay of treatment in moderate?to?severe major depression. During the last 20 years, selective serotonin reuptake inhibitors (SSRIs) have progressively become the most commonly prescribed antidepressants. Citalopram, one of the first SSRIs introduced in the market, is the racemic mixture of S? and R?enantiomer. In the present review we assessed the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with all other antidepressants in the acute?phase treatment of major depression. Thirty?seven randomised controlled trials (more than 6000 participants) were included in the present review. In terms of efficacy, citalopram was more efficacious than other reference compounds like paroxetine or reboxetine, but worse than escitalopram. In terms of side effects, citalopram was more acceptable than older antidepressants, like tricyclics. Based on these findings, we conclude that clinicians should focus on practical or clinically relevant considerations including differences in efficacy and side?effect profiles.
Abstract
Background: Recent US and UK clinical practice guidelines recommend that second?generation antidepressants should be considered amongst the best first?line options when drug therapy is indicated for a depressive episode. Systematic reviews have already highlighted some differences in efficacy between second?generation antidepressants. Citalopram, one of the first selective serotonin reuptake inhibitors (SSRI) introduced in the market, is one of these antidepressant drugs that clinicians use for routine depression care.
Objectives: To assess the evidence for the efficacy, acceptability and tolerability of citalopram in comparison with tricyclics, heterocyclics, other SSRIs and other conventional and non?conventional antidepressants in the acute?phase treatment of major depression.
Search methods: We searched The Cochrane Collaboration Depression, Anxiety and Neurosis Controlled Trials Register and the Cochrane Central Register of Controlled Trials up to February 2012. No language restriction was applied. We contacted pharmaceutical companies and experts in this field for supplemental data.
Selection criteria: Randomised controlled trials allocating patients with major depression to citalopram versus any other antidepressants.
Data collection and analysis: Two reviewers independently extracted data. Information extracted included study characteristics, participant characteristics, intervention details and outcome measures in terms of efficacy (the number of patients who responded or remitted), patient acceptability (the number of patients who failed to complete the study) and tolerability (side?effects).
Main results: Thirty?seven trials compared citalopram with other antidepressants (such as tricyclics, heterocyclics, SSRIs and other antidepressants, either conventional ones, such as mirtazapine, venlafaxine and reboxetine, or non?conventional, like hypericum). Citalopram was shown to be significantly less effective than escitalopram in achieving acute response (odds ratio (OR) 1.47, 95% confidence interval (CI) 1.08 to 2.02), but more effective than paroxetine (OR 0.65, 95% CI 0.44 to 0.96) and reboxetine (OR 0.63, 95% CI 0.43 to 0.91). Significantly fewer patients allocated to citalopram withdrew from trials due to adverse events compared with patients allocated to tricyclics (OR 0.54, 95% CI 0.38 to 0.78) and fewer patients allocated to citalopram reported at least one side effect than reboxetine or venlafaxine (OR 0.64, 95% CI 0.42 to 0.97 and OR 0.46, 95% CI 0.24 to 0.88, respectively).
Authors' conclusions: Some statistically significant differences between citalopram and other antidepressants for the acute phase treatment of major depression were found in terms of efficacy, tolerability and acceptability. Citalopram was more efficacious than paroxetine and reboxetine and more acceptable than tricyclics, reboxetine and venlafaxine, however, it seemed to be less efficacious than escitalopram. As with most systematic reviews in psychopharmacology, the potential for overestimation of treatment effect due to sponsorship bias and publication bias should be borne in mind when interpreting review findings. Economic analyses were not reported in the included studies, however, cost effectiveness information is needed in the field of antidepressant trials.
Source: https://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0047318/
Saturday, July 4, 2026
Prednisone and birth control Explained: A Clear Overview
Doctors prescribe corticosteroids for a wide range of conditions, from inflammation to autoimmune disorders. Sleep disruption is a frequently reported side effect, especially when doses are taken later in the day. Keeping a symptom journal can help identify patterns and guide follow-up conversations with a doctor. Seasonal allergies can flare unpredictably, and short steroid courses sometimes provide fast relief. Every prescription should be taken exactly as directed to reduce the risk of complications. Some conditions respond well to a short burst of treatment, while others need a longer tapering schedule. Older adults may be more sensitive to certain side effects and often start on lower doses. This prednisone and birth control breaks down the key points in an easy-to-follow format. Skin conditions like eczema sometimes respond well to topical or short oral courses. Abruptly stopping a steroid regimen can cause the adrenal glands to struggle to resume normal hormone output. Long-term use requires closer monitoring due to potential effects on bone density and blood sugar. Insurance coverage and pricing can vary widely, so comparing options is often worthwhile. Nutrition plays a supporting role in recovery, particularly for conditions involving inflammation. Mild swelling or water retention sometimes accompanies steroid use and usually resolves after tapering. Taking a dose earlier in the morning can help minimize interference with nightly rest. Corticosteroids mimic hormones the body produces naturally in the adrenal glands. Muscle aches and fatigue are among the more common complaints reported during treatment. Hydration and a balanced diet can support the body during a course of treatment. Inflammation is the body's natural response to injury or infection, but when it becomes chronic it can cause real harm. Mood changes, including irritability or anxiety, are worth mentioning to a healthcare provider. For readers who want a deeper dive, this prednisone tablets covers the specifics in plain language. Missing a dose occasionally is common, but a consistent schedule improves overall outcomes. Pharmacists are a valuable resource for questions about timing, storage, and interactions. Taking medication with food can help reduce stomach discomfort for many patients. With the right guidance, most patients navigate their treatment course safely and effectively.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.